PLX · Protalix BioTherapeutics, Inc. · Executive Compensation
$2.79
+0.08 (+2.95%)
At close · Oct 6
Return incl. dividend (before tax)
Market Cap
$219.15M
Shares
80.57M
Volume · Oct 5
984.06K
Avg daily vol (3M)
720.45K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Dror Bashan | President and Chief Executive Officer | $2,684,941 |
| Eyal Rubin | Senior Vice President and Chief Financial Officer | $1,029,035 |
| Yaron Naos | Senior Vice President, Operations | $776,369 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Dror Bashan | President and Chief Executive Officer | $1,468,296 |
| Eyal Rubin | Senior Vice President and Chief Financial Officer | $1,058,281 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Dror Bashan | President and Chief Executive Officer | $1,157,699 |
| Eyal Rubin | Senior Vice President, Chief Financial Officer | $836,824 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Dror Bashan | President and Chief Executive Officer | $1,341,952 |
| Eyal Rubin | Senior Vice President, Chief Financial Officer | $920,099 |
| Einat Brill Almon | Senior Vice President, Chief Development Officer | $884,666 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Eyal Rubin | Vice President and Chief Financial Officer | Resigned | 2025-07-21 |
| Gilad Mamlok | Senior Vice President and Chief Financial Officer | Appointed | 2025-07-21 |
| Eyal Rubin | Sr. Vice President and Chief Financial Officer | Resigned | 2025-04-23 |
| Zeev Bronfeld | Chairman of the Board | Retired | 2023-09-12 |
| Eliot Richard Forster, Ph.D. | Chairman of the Company's Board of Directors | Appointed | 2023-09-12 |